Upstate Active Clinical Trials

Study Title:

A031701-A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

What is the purpose of the study? (in Layman's terms, please describe the study)

This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Upstate Institutional Review Board (IRB) Number:

1348966

Study/Protocol ID:

A031701

Study Phase:

II

Patient Age Group:

Adults

Principal Investigator:

Alina Basnet

What is involved if I participate?

• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No

Where will the study take place?

Upstate Cancer Center - All procedures
Oneida - All procedures
Oswego - All procedures

ClinicalTrials.Gov ID:

NCT03609216

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Jennifer Newman
Phone: 315-464-8230
Email: [email protected]

Return to Previous Page || Search Again